An ontology model supporting multiple ontologies for knowledge sharing

V. Tamma

Abstract:

What problem does this paper attempt to address?

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Jiajun Zou,Haijia Mao,Fandong Zhu,Bin He,Li Zhao,Chen Yang,Zhenhua Zhao

DOI: https://doi.org/10.21203/rs.3.rs-1746619/v1

2022-01-01

Abstract:Abstract Purpose: In this study, a non-invasive radiomics method was used to extract a large amount of valuable information from patient CT images (including pre-treatment and follow-up images), and the image features were effectively combined with treatment effect evaluation, aiming to solve the problem of lung adenocarcinoma in patients with EGFR mutation positive. The early efficacy evaluation of cancer EGFR-TKI targeted drugs provides a scientific basis for clinical drug selection and adjustment of treatment plans. Methods: It is planned to include 106 patients with EGFR-TKI targeted therapy for lung adenocarcinoma in Shaoxing People's Hospital (pathologically confirmed EGFR mutation positive), and randomly divide them into a training group and a validation group in a ratio of 7:3. The CT plain scan images of patients before and 2 months after treatment were collected, and the images were segmented by ITK-SNAP software. Perform feature screening and modeling, and draw nomograms, calibration curves, and decision curves. Results: After Lasso dimensionality reduction, three features with non-zero coefficients are extracted between groups, sumEntropy,LongRunLowGreyLevelEmphasis_angle0_offset1, LongRunLowGreyLevelEmphasis_angle0_offset4. The average area under the curve (AUC) of the logistic regression model in the training group and the validation group was 0.778 and 0.773, respectively; the Nomogram chart showed that after the three radiomics parameters were scored, the total score was 0-130, and the corresponding effective The risk was 0.1-0.9; the calibration curve showed that the predicted value and the actual clinical observation value approached a 45° slope, indicating that the model was well calibrated; while the decision curve radiomics model was used to evaluate EGFR-TKI in lung adenocarcinoma Targeted drugs have better clinical benefits when they have early efficacy. Conclusions: The radiomics model established based on the radiomics features of CT unenhanced images has good performance in evaluating the efficacy of EGFR-TKI targeted drugs in the treatment of lung adenocarcinoma, and the final Nomogram map can quantitatively evaluate the curative effect, providing individual patient information.
Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features

Jian-Ling Tan,Liang Xia,Su-Guang Sun,Hui Zeng,Di-Yu Lu,Xiao-Jie Cheng

2023-10-20

Abstract:The earlier identification of EGFR mutation status in lung adenocarcinoma patients is crucial for treatment decision-making. Radiomics, which involves high-throughput extraction of imaging features from medical images for quantitative analysis, can quantify tumor heterogeneity and assess tumor biology non-invasively. This field has gained attention from researchers in recent years. The aim of this study is to establish a model based on 18F-FDG PET/CT radiomic features to predict the epidermal growth factor receptor (EGFR) mutation status of lung adenocarcinoma and evaluate its performance. 155 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT scans and EGFR gene detection before treatment were retrospectively analyzed. The LIFEx packages was used to perform 3D volume of interest (VOI) segmentation manually on DICOM images and extract 128 radiomic features. The Wilcoxon rank sum test and least absolute shrinkage and selection operator (LASSO) regression algorithm were applied to filter the radiomic features and establish models. The performance of the models was evaluated by the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Among the models we have built, the radiomic model based on 18F-FDG PET/CT has the best prediction performance for EGFR gene mutation status, with an AUC of 0.90 (95% CI 0.84~0.96) in the training set and 0.79 (95% CI 0.64~0.94) in the test set. In conclusion, we have established a radiomics model based on 18F-FDG PET/CT, which has good predictive performance in identifying EGFR gene mutation status in lung adenocarcinoma patients.
Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Yi Zhou,Xue-Lei Ma,Lu-Tong Pu,Ruo-Fan Zhou,Xue-Jin Ou,Rong Tian

DOI: https://doi.org/10.1155/2019/5963607

2019-01-01

Abstract:Purpose. To determine whether the radiomic features of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) contribute to prognosis prediction in primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. Methods. This retrospective study included 35 PG-DLBCL patients who underwent PET/CT scans at West China Hospital before curative treatment. The volume of interest (VOI) was drawn around the tumor, and radiomic analysis of the PET and CT images, within the same VOI, was conducted. The metabolic and textural features of PET and CT images were evaluated. Correlations of the extracted features with the overall survival (OS) and progression-free survival (PFS) were evaluated. Univariate and multivariate analyses were conducted to assess the prognostic value of the radiomic parameters. Results. In the univariate model, many of the textural features, including kurtosis and volume, extracted from the PET and CT datasets were significantly associated with survival (5 for OS and 7 for PFS (PET); 7 for OS and 14 for PFS (CT)). Multivariate analysis identified kurtosis (hazard ratio (HR): 28.685, 95% confidence interval (CI): 2.067–398.152, p=0.012), metabolic tumor volume (MTV) (HR: 26.152, 95% CI: 2.089–327.392, p=0.011), and gray-level nonuniformity (GLNU) (HR: 14.642, 95% CI: 2.661–80.549, p=0.002) in PET and sphericity (HR: 11.390, 95% CI: 1.360–95.371, p=0.025) and kurtosis (HR: 11.791, 95% CI: 1.583–87.808, p=0.016), gray-level nonuniformity (GLNU) (HR: 6.934, 95% CI: 1.069–44.981, p=0.042), and high gray-level zone emphasis (HGZE) (HR: 9.805, 95% CI: 1.359–70.747, p=0.024) in CT as independent prognostic factors. Conclusion. 18F-FDG PET/CT radiomic features are potentially useful for survival prediction in PG-DLBCL patients. However, studies with larger cohorts are needed to confirm the clinical prognostication of these parameters.
Predicting EGFR Mutation Subtypes in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

Qiufang Liu,Dazhen Sun,Nan Li,Jinman Kim,Dagan Feng,Gang Huang,Lisheng Wang,Shaoli Song

DOI: https://doi.org/10.21037/tlcr.2020.04.17

2020-01-01

Translational Lung Cancer Research

Abstract:Background: Identification of epidermal growth factor receptor (EGFR) mutation types is crucial before tyrosine kinase inhibitors (TKIs) treatment. Radiomics is a new strategy to noninvasively predict the genetic status of cancer. In this study, we aimed to develop a predictive model based on F-18-fluorodeoxyglucose positron emission tomography-computed tomography (F-18-FDG PET/CT) radiomic features to identify the specific EGFR mutation subtypes. Methods: We retrospectively studied F-18-FDG PET/CT images of 148 patients with isolated lung lesions, which were scanned in two hospitals with different CT scan setting (slice thickness: 3 and 5 mm, respectively). The tumor regions were manually segmented on PET/CT images, and 1,570 radiomic features (1,470 from CT and 100 from PET) were extracted from the tumor regions. Seven hundred and ninety-four radiomic features insensitive to different CT settings were first selected using the Mann white U test, and collinear features were further removed from them by recursively calculating the variation inflation factor. Then, multiple supervised machine learning models were applied to identify prognostic radiomic features through: (I) a multi-variate random forest to select features of high importance in discriminating different EGFR mutation status; (II) a logistic regression model to select features of the highest predictive value of the EGFR subtypes. The EGFR mutation predicting model was constructed from prognostic radiomic features using the popular Xgboost machine-learning algorithm and validated using 3-fold cross-validation. The performance of predicting model was analyzed using the receiver operating characteristic curve (ROC) and measured with the area under the curve (AUC). Results: Two sets of prognostic radiomic features were found for specific EGFR mutation subtypes: 5 radiomic features for EGFR exon 19 deletions, and 5 radiomic features for EGFR exon 21 L858R missense. The corresponding radiomic predictors achieved the prediction accuracies of 0.77 and 0.92 in terms of AUC, respectively. Combing these two predictors, the overall model for predicting EGFR mutation positivity was also constructed, and the AUC was 0.87. Conclusions: In our study, we established predictive models based on radiomic analysis of F-18-FDG PET/CT images. And it achieved a satisfying prediction power in the identification of EGFR mutation status as well as the certain EGFR mutation subtypes in lung cancer.
A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)

Ying Zhu,Yu-Biao Guo,Di Xu,Jing Zhang,Zhen-Guo Liu,Xi Wu,Xiao-Yu Yang,Dan-Dan Chang,Min Xu,Jing Yan,Zun-Fu Ke,Shi-Ting Feng,Yang-Li Liu

DOI: https://doi.org/10.21037/atm-20-6473

IF: 3.616

2021-04-01

Annals of Translational Medicine

Abstract:BACKGROUND: Epidermal growth factor receptor (EGFR) co-mutated with TP53 could reduce responsiveness to tyrosine kinase inhibitors (TKIs) and worsen patients' prognosis compared to TP53 wild type patients in.EGFR: mutated lung adenocarcinomas (LUAD). To identify this genetically unique subset prior to treatment through computed tomography (CT) images had not been reported yet.METHODS: Stage III and IV LUAD with known mutation status of EGFR and TP53 from The First Affiliated Hospital of Sun Yat-sen University (May 1, 2017 to June 1, 2020) were collected. Characteristics of pretreatment enhanced-CT images were analyzed. One-versus-one was used as the multiclass classification strategy to distinguish the three subtypes of co-mutations: EGFR + & TP53 +, EGFR + & TP53 -, EGFR -. The clinical model, semantic model, radiomics model and integrated model were built. Area under the receiver-operating characteristic curves (AUCs) were used to evaluate the prediction efficacy.RESULTS: A total of 199 patients were enrolled, including 83 (42%) cases of EGFR -, 55 (28%) cases of EGFR + & TP53 +, 61 (31%) cases of EGFR + & TP53 -. Among the four different models, the integrated model displayed the best performance for all the three subtypes of co-mutations: EGFR - (AUC, 0.857; accuracy, 0.817; sensitivity, 0.998; specificity, 0.663), EGFR + & TP53 + (AUC, 0.791; accuracy, 0.758; sensitivity, 0.762; specificity, 0.783), EGFR + & TP53 - (AUC, 0.761; accuracy, 0.813; sensitivity, 0.594; specificity, 0.977). The radiomics model was slightly inferior to the integrated model. The results for the clinical and the semantic models were dissatisfactory, with AUCs less than 0.700 for all the three subtypes.CONCLUSIONS: CT imaging based artificial intelligence (AI) is expected to distinguish co-mutation status involving TP53 and EGFR. The proposed integrated model may serve as an important alternative marker for preselecting patients who will be adaptable to and sensitive to TKIs.

oncology,medicine, research & experimental
Optimal 18F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study

Yan Zuo,Qiufang Liu,Nan Li,Panli Li,Jianping Zhang,Shaoli Song

DOI: https://doi.org/10.3389/fonc.2023.1173355

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:PurposeTo develop and interpret optimal predictive models to identify epidermal growth factor receptor (EGFR) mutation status and subtypes in patients with lung adenocarcinoma based on multicentric F-18-FDG PET/CT data, and further construct a prognostic model to predict their clinical outcome. MethodsThe F-18-FDG PET/CT imaging and clinical characters of 767 patients with lung adenocarcinoma from 4 cohorts were collected. Seventy-six radiomics candidates using cross-combination method to identity EGFR mutation status and subtypes were built. Further, Shapley additive explanations and local interpretable model-agnostic explanations were used for optimal models' interpretation. Moreover, in order to predict the overall survival, a multivariate Cox proportional hazard model based on handcrafted radiomics features and clinical characteristics was constructed. The predictive performance and clinical net benefit of the models were evaluated via area under receiver operating characteristic (AUC), C-index and decision curve analysis. ResultsAmong the 76 radiomics candidates, light gradient boosting machine classifier (LGBM) combined with recursive feature elimination wrapped LGBM feature selection method achieved best performance in predicting EGFR mutation status (AUC reached 0.80, 0.61, 0.71 in the internal test cohort and two external test cohorts, respectively). And extreme gradient boosting classifier combined with support vector machine feature selection method achieved best performance in predicting EGFR subtypes (AUC reached 0.76, 0.63, 0.61 in the internal test cohort and two external test cohorts, respectively). The C-index of the Cox proportional hazard model achieved 0.863. ConclusionsThe integration of cross-combination method and the external validation from multi-center data achieved a good prediction and generalization performance in predicting EGFR mutation status and its subtypes. The combination of handcrafted radiomics features and clinical factors achieved good performance in predicting prognosis. With the urgent needs of multicentric F-18-FDG PET/CT trails, robust and explainable radiomics models have great potential in decision making and prognosis prediction of lung adenocarcinoma.
18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Bin Yang,Heng-Shan Ji,Chang-Sheng Zhou,Hao Dong,Lu Ma,Ying-Qian Ge,Chao-Hui Zhu,Jia-He Tian,Long-Jiang Zhang,Hong Zhu,Guang-Ming Lu

DOI: https://doi.org/10.21037/tlcr-19-592

2020-01-01

Translational Lung Cancer Research

Abstract:Background: To investigate whether radiomic features from (F-18)-fluorodeoxyglucose positron emission tomography/computed tomography [(F-18)-FDG PET/CT] can predict epidermal growth factor receptor (EGFR) mutation status and prognosis in patients with lung adenocarcinoma. Methods: One hundred and seventy-four consecutive patients with lung adenocarcinoma underwent (F-18)-FDG PET/CT and EGFR gene testing were retrospectively analyzed. Radiomic features combined with clinicopathological factors to construct a random forest (RF) model to identify EGFR mutation status. The mutant/wild-type model was trained on a training group (n=139) and validated in an independent validation group (n=35). The second RF classifier predicting the 19/21 mutation site was also built and evaluated in an EGFR mutation subset (training group, n=80; validation group, n=25). Radiomic score and 5 clinicopathological factors were integrated into a multivariate Cox proportional hazard (CPH) model for predicting overall survival (OS). AUC (the area under the receiver characteristic curve) and C-index were calculated to evaluate the model's performance. Results: Of 174 patients, 109 (62.6%) harbored EGFR mutations, 21L858R was the most common mutation type [55.9% (61/109)]. The mutant/wild-type model was identified in the training (AUC, 0.77) and validation (AUC, 0.71) groups. The 19/21 mutation site model had an AUC of 0.82 and 0.73 in the training and validation groups, respectively. The C-index of the CPH model was 0.757. The survival time between targeted therapy and chemotherapy for patients with EGFR mutations was significantly different (P=0.03). Conclusions: Radiomic features based on (F-18)-FDG PET/CT combined with clinicopathological factors could reflect genetic differences and predict EGFR mutation type and prognosis.
Subregion-specific 18F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma

Yun Wang,Guang Yang,Xinyi Gao,Linfa Li,Hongzhou Zhu,Heqing Yi

DOI: https://doi.org/10.62347/DDRR4923

2024-04-25

Abstract:This study aimed to assess the efficacy of fluor-18 fluorodeoxyglucose (18F-FDG) PET/CT using sub-regional-based radiomics in predicting epidermal growth factor receptor (EGFR) mutation status in pretreatment patients with solid lung adenocarcinoma. A retrospective analysis included 269 patients (134 EGFR+ and 135 EGFR-) who underwent pretreatment 18F-FDG PET/CT scans and EGFR mutation testing. The most metabolically active intratumoral sub-region was identified, and radiomics features from whole tumors or sub-regional regions were used to build classification models. The dataset was split into a 7:3 ratio for training and independent testing. Feature subsets were determined by Pearson correlation and the Kruskal Wallis test and radiomics classifiers were built with support vector machines or logistic regressions. Evaluation metrics, including accuracy, area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were employed for different classifiers. Results indicated that the sub-region-based classifier outperformed the whole-tumor classifier in terms of accuracy (73.8% vs. 66.2%), AUC (0.768 vs. 0.632), specificity (65.0% vs. 50.0%), PPV (70.2% vs. 62.2%), and NPV (78.8% vs. 74.0%). The clinical classifier exhibited an accuracy of 75.0%, AUC of 0.768, sensitivity of 72.5%, specificity of 77.5%, PPV of 76.3%, and NPV of 73.8%. The combined classifier, incorporating sub-region analysis and clinical parameters, demonstrated further improvement with an accuracy of 77.5%, AUC of 0.807, sensitivity of 77.5%, specificity of 77.5%, and NPV of 77.5%. The study suggests that sub-region-based 18F-FDG PET/CT radiomics enhances EGFR mutation prediction in solid lung adenocarcinoma, providing a practical and cost-efficient alternative to invasive EGFR testing.
Predicting Gene Comutation of EGFR and TP53 by Radiomics and Deep Learning in Patients With Lung Adenocarcinomas

Xiao-yan Wang,Shao-hong Wu,Jiao Ren,Yan Zeng,Li-li Guo

DOI: https://doi.org/10.1097/rti.0000000000000817

IF: 5.528

2024-09-25

Journal of Thoracic Imaging

Abstract:Purpose: This study was designed to construct progressive binary classification models based on radiomics and deep learning to predict the presence of epidermal growth factor receptor ( EGFR ) and TP53 mutations and to assess the models’ capacities to identify patients who are suitable for TKI-targeted therapy and those with poor prognoses. Materials and Methods: A total of 267 patients with lung adenocarcinomas who underwent genetic testing and noncontrast chest computed tomography from our hospital were retrospectively included. Clinical information and imaging characteristics were gathered, and high-throughput feature acquisition on all defined regions of interest (ROIs) was carried out. We selected features and constructed clinical models, radiomics models, deep learning models, and ensemble models to predict EGFR status with all patients and TP53 status with EGFR-positive patients, respectively. The validity and reliability of each model were expressed as the area under the curve (AUC), sensitivity, specificity, accuracy, precision, and F1 score. Results: We constructed 7 kinds of models for 2 different dichotomies, namely, the clinical model, the radiomics model, the DL model, the rad-clin model, the DL-clin model, the DL-rad model, and the DL-rad-clin model. For EGFR − and EGFR +, the DL-rad-clin model got the highest AUC value of 0.783 (95% CI: 0.677-0.889), followed by the rad-clin model, the DL-clin model, and the DL-rad model. In the group with an EGFR mutation, for TP53 − and TP53 +, the rad-clin model got the highest AUC value of 0.811 (95% CI: 0.651-0.972), followed by the DL-rad-clin model and the DL-rad model. Conclusion: Our progressive binary classification models based on radiomics and deep learning may provide a good reference and complement for the clinical identification of TKI responders and those with poor prognoses.

radiology, nuclear medicine & medical imaging
Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer

Jianyuan Zhang,Xinming Zhao,Yan Zhao,Jingmian Zhang,Zhaoqi Zhang,Jianfang Wang,Yingchen Wang,Meng Dai,Jingya Han

DOI: https://doi.org/10.1007/s00259-019-04592-1

2019-11-14

Abstract:PurposeTo assess the predictive power of pre-therapy 18F-FDG PET/CT-based radiomic features for epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer.MethodsTwo hundred and forty-eight lung cancer patients underwent pre-therapy diagnostic 18F-FDG PET/CT scans and were tested for genetic mutations. The LIFEx package was used to extract 47 PET and 45 CT radiomic features reflecting tumor heterogeneity and phenotype. The least absolute shrinkage and selection operator (LASSO) algorithm was used to select radiomic features and develop a radiomics signature. We compared the predictive performance of models established by radiomics signature, clinical variables, and their combinations using receiver operating curves (ROCs). In addition, a nomogram based on the radiomics signature score (rad-score) and clinical variables was developed.ResultsThe patients were divided into a training set (n = 175) and a validation set (n = 73). Ten radiomic features were selected to build the radiomics signature model. The model showed a significant ability to discriminate between EGFR mutation and EGFR wild type, with area under the ROC curve (AUC) equal to 0.79 in the training set, and 0.85 in the validation set, compared with 0.75 and 0.69 for the clinical model. When clinical variables and radiomics signature were combined, the AUC increased to 0.86 (95% CI [0.80–0.91]) in the training set and 0.87 (95% CI [0.79–0.95]) in the validation set, thus showing better performance in the prediction of EGFR mutations.ConclusionThe PET/CT-based radiomic features showed good performance in predicting EGFR mutation in non-small cell lung cancer, providing a useful method for the choice of targeted therapy in a clinical setting.

radiology, nuclear medicine & medical imaging
Mammalian cell production and purification of progenipoietin, a dual‐agonist chimaeric haematopoietic growth factor

David C. Wood,K. Mathis,W. Joy,J. Minnerly,L. Pegg,J. K. Welply

DOI: https://doi.org/10.1042/BA20020046

2003-02-01

Biotechnology and Applied Biochemistry

Abstract:One member of the progenipoietin (ProGP) family of engineered proteins, ProGP‐2, is a chimaeric dual cytokine receptor agonist, expressed in mammalian cells, that stimulates both human fetal liver tyrosine kinase‐3 (Flt3) and the granulocyte‐colony‐stimulating‐factor (G‐CSF) receptor. The production of ProGP‐2 on a small and large scale using either anti‐(Flt3 ligand) antibody‐affinity chromatography, or a combination of (NH4)2SO4 fractionation, anion‐exchange chromatography, hydrophobic‐interaction chromatography and preparative reverse‐phase chromatography is described. ProGP‐2 was produced in hollow‐fibre reactors containing stably transfected NS0 cells. The productivity of ProGP‐2 was initially high, but was found to decrease 3–4‐fold over time. When the yield of ProGP‐2 decreased, the combination of three conventional chromatography steps was required to meet protein purity similar to that achieved by the anti‐(Flt3 ligand) chromatography method. In addition, a protease activity was observed in conditioned media from the hollow‐fibre reactors that resulted in increased degradation of ProGP‐2 that was removed by hydrophobic‐interaction chromatography at higher pH. Together the results demonstrated a method for production and purification of ProGP‐2 for additional studies on its haematopoietic activity.
EGFR mutation prediction using F18-FDG PET-CT based radiomics features in non-small cell lung cancer

Hector Henriquez,Diana Fuentes,Francisco Suarez,Patricio Gonzalez

2023-03-14

Abstract:Lung cancer is the leading cause of cancer death in the world. Accurate determination of the EGFR (epidermal growth factor receptor) mutation status is highly relevant for the proper treatment of this patients. Purpose: The aim of this study was to predict the mutational status of the EGFR in non-small cell lung cancer patients using radiomics features extracted from PET-CT images. Methods: Retrospective study that involve 34 patients with lung cancer confirmed by histology and EGFR status mutation assessment. A total of 2.205 radiomics features were extracted from manual segmentation of the PET-CT images using pyradiomics library. Both computed tomography and positron emission tomography images were used. All images were acquired with intravenous iodinated contrast and F18-FDG. Preprocessing includes resampling, normalization, and discretization of the pixel intensity. Three methods were used for the feature selection process: backward selection (set 1), forward selection (set 2), and feature importance analysis of random forest model (set 3). Nine machine learning methods were used for radiomics model building. Results: 35.2% of patients had EGFR mutation, without significant differences in age, gender, tumor size and SUVmax. After the feature selection process 6, 7 and 17 radiomics features were selected, respectively in each group. The best performances were obtained by Ridge Regression in set 1: AUC of 0.826 (95% CI, 0.811 - 0.839), Random Forest in set 2: AUC of 0.823 (95% CI, 0.808 - 0.838) and Neural Network in set 3: AUC of 0.821 (95% CI, 0.808 - 0.835). Conclusion: The radiomics features analysis has the potential of predicting clinically relevant mutations in lung cancer patients through a non-invasive methodology.

Quantitative Methods,Artificial Intelligence,Machine Learning
Dual-energy CT-based Radiomics in Predicting EGFR Mutation Status Non-Invasively in Lung Adenocarcinoma

Jing-Wen Ma,Xu Jiang,Yan-Mei Wang,Jiu-Ming Jiang,Lei Miao,Lin -Lin Qi,Jia-Xing Zhang,Xin Wen,Jian-Wei Li,Meng Li,Li Zhang

DOI: https://doi.org/10.1016/j.heliyon.2024.e24372

IF: 3.776

2024-01-01

Heliyon

Abstract:Objectives: Patients with epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LUAD) can benefit from individualized targeted therapy. This study aims to develop, compare, analyse prediction models based on dual-energy spectral computed tomography (DESCT) and CT-based radiomic features to non-invasively predict EGFR mutation status in LUAD. Materials and methods: Patients with LUAD (n = 175), including 111 patients with and 64 patients without EGFR mutations, were enrolled in the current study. All patients were randomly divided into a training dataset (122 cases) and validation dataset (53 cases) at a ratio of 7:3. After extracting CT-based radiomic, DESCT and clinical features, we built seven prediction models and a nomogram of the best prediction. Receiver operating characteristic (ROC) curves and the mean area under the curve (AUC) values were used for comparisons among the models to obtain the best prediction model for predicting EGFR mutations. Results: The best distinguishing ability is the combined model incorporating radiomic, DESCT and clinical features for predicting the EGFR mutation status with an AUC of 0.86 (95 % CI: 0.79-0.92) in the training group and an AUC value of 0.83 (95 % CI: 0.73, 0.96) in the validation group. Conclusions: Our study provides a predictive nomogram non-invasively with a combination of CTbased radiomic, DESCT and clinical features, which can provide image-based biological information for targeted therapy of LUAD with EGFR mutations.
Value of multi‐center 18F‐FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma

Yan Zuo,Liu Liu,Cheng Chang,Hui Yan,Lihua Wang,Dazhen Sun,Maomei Ruan,Bei Lei,Xunpeng Xia,Wenhui Xie,Shaoli Song,Gang Huang

DOI: https://doi.org/10.1002/mp.16947

IF: 4.506

2024-01-31

Medical Physics

Abstract:Background Accurate, noninvasive, and reliable assessment of epidermal growth factor receptor (EGFR) mutation status and EGFR molecular subtypes is essential for treatment plan selection and individualized therapy in lung adenocarcinoma (LUAD). Radiomics models based on 18F‐FDG PET/CT have great potential in identifying EGFR mutation status and EGFR subtypes in patients with LUAD. The validation of multi‐center data, model visualization, and interpretation are significantly important for the management, application and trust of machine learning predictive models. However, few EGFR‐related research involved model visualization and interpretation, and multi‐center trial. Purpose To develop explainable optimal predictive models based on handcrafted radiomics features (HRFs) extracted from multi‐center 18F‐FDG PET/CT to predict EGFR mutation status and molecular subtypes in LUAD. Methods Baseline 18F‐FDG PET/CT images of 383 LUAD patients from three hospitals and one public data set were collected. Further, 1808 HRFs were extracted from the primary tumor regions using Pyradiomics. Predictive models were built based on cross‐combination of seven feature selection methods and seven machine learning algorithms. Yellowbrick and explainable artificial intelligence technology were used for model visualization and interpretation. Receiver operating characteristic curve, classification report and confusion matrix were used for model performance evaluation. Clinical applicability of the optimal models was assessed by decision curve analysis. Results STACK feature selection method combined with light gradient boosting machine (LGBM) reached optimal performance in identifying EGFR mutation status ([area under the curve] AUC = 0.81 in the internal test cohort; AUC = 0.62 in the external test cohort). Random forest feature selection method combined with LGBM reached optimal performance in predicting EGFR mutation molecular subtypes (AUC = 0.89 in the internal test cohort; AUC = 0.61 in the external test cohort). Conclusions Explainable machine learning models combined with radiomics features extracted from multi‐center/scanner 18F‐FDG PET/CT have certain potential to identify EGFR mutation status and subtypes in LUAD, which might be helpful to the treatment of LUAD.

radiology, nuclear medicine & medical imaging
PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Liping Yang,Panpan Xu,Mengyue Li,Menglu Wang,Mengye Peng,Ying Zhang,Tingting Wu,Wenjie Chu,Kezheng Wang,Hongxue Meng,Lingbo Zhang

DOI: https://doi.org/10.3389/fonc.2022.894323

IF: 4.7

2022-06-21

Frontiers in Oncology

Abstract:Backgrounds: Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this study was to evaluate the predictive efficacy of baseline 18 F-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy. Methods: A sum of 313 NSCLC patients with pre-treatment 18 F-FDG PET/CT scans and genetic mutations detection were retrospectively studied. Clinical and PET metabolic parameters were incorporated into independent predictors of determining mutation status and mutation site. The dataset was randomly allocated into the training and the validation sets in a 7:3 ratio. Three-dimensional (3D) radiomics features were extracted from each PET- and CT-volume of interests (VOI) singularly, and then a radiomics signature (RS) associated with EGFR mutation profiles is built by feature selection. Three different prediction models based on support vector machine (SVM), decision tree (DT), and random forest (RF) classifiers were established. Furthermore, nomograms for estimation of overall survival (OS) and progression-free survival (PFS) were established by integrating PET/CT radiomics score (Rad-score), metabolic parameters, and clinical factors. Predictive performance was assessed by the receiver operating characteristic (ROC) analysis and the calibration curve analysis. The decision curve analysis (DCA) was applied to estimate and compare the clinical usefulness of nomograms. Results: Three hundred thirteen NSCLC patients were classified into a training set (n=218) and a validation set (n=95). Multivariate analysis demonstrated that SUVmax and sex were independent indicators of EGFR mutation status and mutation site. Eight CT-derived RS, six PET-derived RS, and two clinical factors were retained to develop integrated models, which exhibited excellent ability to distinguish between EGFR wild type (EGFR-WT), EGFR 19 mutation type (EGFR-19-MT), and EGFR 21 mutation type (EGFR-21-MT). The SVM model outperformed the RF model and the DT model, yielding training area under the curves (AUC) of EGFR-WT, EGFR-19-WT, and EGFR-21-WT, with 0.881, 0.851, and 0.849, respectively, and validation AUCs of 0.926, 0.805 and 0.859, respectively. For prediction of OS, the integrated nomogram is superior to the clinical nomogram and the radiomics nomogram, with C-indexes of 0.80 in the training set and 0.83 in the validation set, respectively. Conclusions: The PET/CT-based radiomics analysis might provide a novel approach to predict EGFR mutation status and mutation site in NSCLC patients and could serve as useful predictors for the patients' survival outcome of targeted therapy in clinical practice.

oncology
Computed Tomography-derived Intratumoral and Peritumoral Radiomics in Predicting EGFR Mutation in Lung Adenocarcinoma.

Youlan Shang,Weidao Chen,Ge Li,Yijie Huang,Yisong Wang,Xiaoyan Kui,Ming Li,Hairong Zheng,Wei Zhao,Jun Liu

DOI: https://doi.org/10.1007/s11547-023-01722-6

2023-01-01

La radiologia medica

Abstract:Objective To investigate the value of Computed Tomography (CT) radiomics derived from different peritumoral volumes of interest (VOIs) in predicting epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma patients. Materials and methods A retrospective cohort of 779 patients who had pathologically confirmed lung adenocarcinoma were enrolled. 640 patients were randomly divided into a training set, a validation set, and an internal testing set (3:1:1), and the remaining 139 patients were defined as an external testing set. The intratumoral VOI (VOI_I) was manually delineated on the thin-slice CT images, and seven peritumoral VOIs (VOI_P) were automatically generated with 1, 2, 3, 4, 5, 10, and 15 mm expansion along the VOI_I. 1454 radiomic features were extracted from each VOI. The t -test, the least absolute shrinkage and selection operator (LASSO), and the minimum redundancy maximum relevance (mRMR) algorithm were used for feature selection, followed by the construction of radiomics models (VOI_I model, VOI_P model and combined model). The performance of the models were evaluated by the area under the curve (AUC). Results 399 patients were classified as EGFR mutant (EGFR+), while 380 were wild-type (EGFR−). In the training and validation sets, internal and external testing sets, VOI4 (intratumoral and peritumoral 4 mm) model achieved the best predictive performance, with AUCs of 0.877, 0.727, and 0.701, respectively, outperforming the VOI_I model (AUCs of 0.728, 0.698, and 0.653, respectively). Conclusions Radiomics extracted from peritumoral region can add extra value in predicting EGFR mutation status of lung adenocarcinoma patients, with the optimal peritumoral range of 4 mm.
Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients

Guojin Zhang,Qiong Man,Lan Shang,Jing Zhang,Yuntai Cao,Shenglin Li,Rong Qian,Jialiang Ren,Hong Pu,Junlin Zhou,Zhuoli Zhang,Weifang Kong

DOI: https://doi.org/10.1016/j.acra.2023.12.024

IF: 5.482

2024-01-01

Academic Radiology

Abstract:RATIONALE AND OBJECTIVES: This study aimed to non-invasively predict epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma using multi-phase computed tomography (CT) radiomics features.MATERIALS AND METHODS: A total of 424 patients with lung adenocarcinoma were recruited from two hospitals who underwent preoperative non-enhanced CT (NE-CT) and enhanced CT (including arterial phase CT [AP-CT], and venous phase CT [VP-CT]). Patients were divided into training (n = 297) and external validation (n = 127) cohorts according to hospital. Radiomics features were extracted from the NE-CT, AP-CT, and VP-CT images, respectively. The Wilcoxon test, correlation analysis, and simulated annealing were used for feature screening. A clinical model and eight radiomics models were established. Furthermore, a clinical-radiomics model was constructed by incorporating multi-phase CT features and clinical risk factors. Receiver operating characteristic curves were used to evaluate the predictive performance of the models.RESULTS: The predictive performance of multi-phase CT radiomics model (AUC of 0.925 [95% CI, 0.879-0.971] in the validation cohort) was higher than that of NE-CT, AP-CT, VP-CT, and clinical models (AUCs of 0.860 [95% CI,0.794-0.927], 0.792 [95% CI, 0.713-0.871], 0.753 [95% CI, 0.669-0.838], and 0.706 [95% CI, 0.620-0.791] in the validation cohort, respectively) (all P < 0.05). The predictive performance of the clinical-radiomics model (AUC of 0.927 [95% CI, 0.882-0.971] in the validation cohort) was comparable to that of multi-phase CT radiomics model (P > 0.05).CONCLUSION: Our multi-phase CT radiomics model showed good performance in identifying the EGFR mutation status in patients with lung adenocarcinoma, which may assist personalized treatment decisions.

radiology, nuclear medicine & medical imaging
Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma

Yu-Hung Chen,Tso-Fu Wang,Sung-Chao Chu,Chih-Bin Lin,Ling-Yi Wang,Kun-Han Lue,Shu-Hsin Liu,Sheng-Chieh Chan

DOI: https://doi.org/10.1371/journal.pone.0244502

IF: 3.7

2020-12-28

PLoS ONE

Abstract:Background To investigate the survival prognostic value of the radiomic features of 18 F-FDG PET in patients who had EGFR (epidermal growth factor receptor) mutated lung adenocarcinoma and received targeted TKI (tyrosine kinase inhibitor) treatment. Methods Fifty-one patients with stage III-IV lung adenocarcinoma and actionable EGFR mutation who received first-line TKI were retrospectively analyzed. All patients underwent pretreatment 18 F-FDG PET/CT, and we calculated the PET-derived radiomic features. Cox proportional hazard model was used to examine the association between the radiomic features and the survival outcomes, including progression-free survival (PFS) and overall survival (OS). A score model was established according to the independent prognostic predictors and we compared this model to the TNM staging system using Harrell's concordance index (c-index). Results Forty-eight patients (94.1%) experienced disease progression and 41 patients (80.4%) died. Primary tumor SUV entropy > 5.36, and presence of pleural effusion were independently associated with worse OS (both p < 0.001) and PFS ( p = 0.001, and 0.003, respectively). We used these two survival predictors to devise a scoring system (score 0–2). Patients with a score of 1 or 2 had a worse survival than those with a score of 0 (HR for OS: 3.6, p = 0.006 for score 1, and HR: 21.8, p < 0.001 for score 2; HR for PFS: 2.2, p = 0.027 for score 1 and HR: 8.8, p < 0.001 for score 2). Our scoring system surpassed the TNM staging system (c-index = 0.691 versus 0.574, p = 0.013 for OS, and c-index = 0.649 versus 0.517, p = 0.004 for PFS). Conclusions In this preliminary study, combining PET radiomics with clinical risk factors may improve survival stratification in stage III-IV lung adenocarcinoma with actionable EFGR mutation. Our proposed scoring system may assist with optimization of individualized treatment strategies in these patients.

multidisciplinary sciences
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas

Ying Liu,Jongphil Kim,Yoganand Balagurunathan,Qian Li,Alberto L Garcia,Olya Stringfield,Zhaoxiang Ye,Robert J Gillies

DOI: https://doi.org/10.1016/j.cllc.2016.02.001

Abstract:Background: In this study we retrospectively evaluated the capability of computed tomography (CT)-based radiomic features to predict epidermal growth factor receptor (EGFR) mutation status in surgically-resected peripheral lung adenocarcinomas in an Asian cohort of patients. Patients and methods: Two hundred ninety-eight patients with surgically resected peripheral lung adenocarcinomas were investigated in this institutional review board-approved retrospective study with requirement waived to obtain informed consent. Two hundred nineteen quantitative 3-D features were extracted from segmented volumes of each tumor, and 59 of these, which were considered independent features, were included in the analysis. Clinical and pathological information was obtained from the institutional database. Results: Mutant EGFR was significantly associated with female sex (P = .0005); never smoker status (P < .0001), lepidic predominant adenocarcinomas (P = .017), and low or intermediate pathologic grade (P = .0002). Statistically significant differences were found in 11 radiomic features between EGFR mutant and wild type groups in univariate analysis. Mutant EGFR status could be predicted by a set of 5 radiomic features that fell into 3 broad groups: CT attenuation energy, tumor main direction, and texture defined according to wavelets and Laws (area under the curve [AUC], 0.647). A multiple logistic regression model showed that adding radiomic features to a clinical model resulted in a significant improvement of predicting power, because the AUC increased from 0.667 to 0.709 (P < .0001). Conclusion: Computed tomography-based radiomic features of peripheral lung adenocarcinomas can capture useful information regarding tumor phenotype, and the model we built can be useful to predict the presence of EGFR mutations in peripheral lung adenocarcinoma in Asian patients when mutational profiling is not available or possible.
A predictive model of computed tomography and clinical features of EGFR gene mutation in lung adenocarcinoma

Youjian Yao,Nengde Zhang,Caiwei Lu,Lianhua Liu,Yu Fu,Mei Gui

DOI: https://doi.org/10.1177/00368504241293008

IF: 1.512

2024-11-06

Science Progress

Abstract:Science Progress, Volume 107, Issue 4, October-December 2024. Purpose: This study aims to develop a predictive model for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma by integrating computed tomography (CT) imaging features with clinical characteristics. Methods: A retrospective analysis was conducted using electronic medical records from 194 patients diagnosed with lung adenocarcinoma between January 2016 and December 2020, with approval from the institutional review board. Features were selected using LASSO regression, and predictive models were built using logistic regression, support vector machine, and random forest methods. Individual models were created for clinical features, CT imaging features, and a combined model to predict EGFR mutations. Results: The training set revealed that alcohol consumption, intrapulmonary metastasis, and pleural effusion were statistically significant in distinguishing between wild-type and mutation groups (p < 0.05). In the testing set, hilar and mediastinal lymphadenopathy showed statistical significance (p < 0.05). The combined model outperformed the individual clinical and CT imaging feature models. In the testing set, the logistic regression model achieved the highest AUC of 0.827, with sensitivity, specificity, and accuracy of 0.714, 0.712, and 0.712, respectively. Nomogram analysis identified lobulation as an important feature, with a predicted probability of up to 0.9. The decision curve analysis showed that the CT imaging feature model provided a higher net benefit compared to both the clinical feature model and the combined model. Conclusion: In summary, while the combined model outperformed the individual feature models in the testing set, the CT imaging feature model demonstrated the greatest clinical net benefit. Lobulation was identified as an important predictor of EGFR mutations in lung adenocarcinoma.

multidisciplinary sciences

An ontology model supporting multiple ontologies for knowledge sharing

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features

Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Predicting EGFR Mutation Subtypes in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)

Optimal <SUP>18</SUP>F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Subregion-specific 18F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma

Predicting Gene Comutation of EGFR and TP53 by Radiomics and Deep Learning in Patients With Lung Adenocarcinomas

Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer

Mammalian cell production and purification of progenipoietin, a dual‐agonist chimaeric haematopoietic growth factor

EGFR mutation prediction using F18-FDG PET-CT based radiomics features in non-small cell lung cancer

Dual-energy CT-based Radiomics in Predicting EGFR Mutation Status Non-Invasively in Lung Adenocarcinoma

Value of multi‐center 18F‐FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Computed Tomography-derived Intratumoral and Peritumoral Radiomics in Predicting EGFR Mutation in Lung Adenocarcinoma.

Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients

Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma

Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas

A predictive model of computed tomography and clinical features of EGFR gene mutation in lung adenocarcinoma